So-called “triple-negative” breast cancer represents between 12 and 17 percent of all breast cancers. It derives its name from the lack of receptors for estrogen, progesterone and Her2. The absence of these receptors rules out proven hormone therapies such as tamoxifen. …
However, the growing trend in developed countries to delay having children until later in life has resulted in egg freezing being increasingly used by healthy women as insurance against age-related infertility. …
Researchers evaluated clinical features and survival outcomes among 41,502 patients diagnosed with stage I and II Hodgkin’s Disease from 1998 to 2011 from a prospectively collected database — the National Cancer Data Base (NCDB), which is composed of cases from 1,500 sites and represents >75 percent of all cancers diagnosed in the U.S. The average patient age was 37 (range: 18 — 90), with a median follow-up of 7.5 years. The association between RT use, co-variables and outcome were assessed in a multivariate Cox proportional hazards model…
“It is well-established that individual tumors are genetically heterogeneous — comprised of multiple subgroups of cancer cells, each with its own genomic signature, or pattern of gene mutations,” said the study’s senior author, Kornelia Polyak, MD, PhD, of Dana-Farber. …
“Tumors located at the base of the skull are particularly challenging to treat due to the location of delicate anatomic structures and critical blood vessels,” said neurosurgeon Clark C. Chen, MD, PhD, UC San Diego Health System. “The conventional approach to excising these tumors involves long skin incisions and removal of a large piece of skull. …
Scientists have made significant strides identifying important molecules that contribute to melanoma growth and metastases, such as the proteins BRAF and MEK. Therapeutic agents that target these molecules have shown promise in the clinic, and many patients have significant reductions in tumor growth and tumor burden. “While targeted therapy drugs, such as BRAF and MEK inhibitors, have been associated with impressive responses in melanoma patients, most patients will eventually fail therapy,” said Keiran Smalley, Ph.D., associate member of the Cancer Biology and Evolution Program at Moffitt. Tumors can develop different resistance mechanisms and adapt to targeted agents in order to survive and continue to grow. …
The study is published the week of June 30, 2014 in Proceedings of the National Academy of Sciences. “Bone is a favorable microenvironment for the growth of cancer cells that migrate from tumors in distant organs of the body, such as breast, prostate and blood, during disease progression,” said Archana Swami, PhD, BWH Laboratory of Nanomedicine and Biomaterials, co-lead study author. …
source : http://www.sciencedaily.com/releases/2014/06/140630124429.htm
source : http://www.sciencedaily.com/releases/2014/04/140414123741.htm
source : http://www.sciencedaily.com/releases/2014/02/140227115426.htm